APUS Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -8.14%, SMA50 -18.09%, SMA200 -27.98%). The stock’s 14-day RSI is 45.21 (neutral), while the ATR of 0.24 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -66.26% below its high and over 43.01% above its low. Average 10-day trading volume of 178.63 thousand shares is below the 3-month average of 229.55 thousand, indicating normal recent market interest.

Apimeds Pharmaceuticals US, Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.56. This means the shares are trading below this model’s fair value.

Apimeds Pharmaceuticals US, Inc (AMEX:APUS) closed at $0.71 USD, losing -$0.02 (-3.35%) from the previous close of $0.73. The stock is currently within 5% of its 52-week low $0.68 and $40.31. With a market capitalization of about $890.25 thousand, Apimeds Pharmaceuticals US, Inc is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.31). Key stats such as the average daily volume over the past year has been around 188.09 thousand shares, volume is running light vs its 52-week average. Headquartered in Hopewell, NJ, Apimeds Pharmaceuticals US, Inc operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Vinod Menon, the company employs approximately 7 people and listed since May 09, 2025. Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States.

Apimeds Pharmaceuticals US, Inc trades at a P/E ratio of -0.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.09 suggesting the stock is closer to book value. The P/FCF stands at -0.08, also above market averages.

Our AI price prediction model suggests that Apimeds Pharmaceuticals US, Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -35.02%, with price expected at $0.46 by July 28, 2026, within a range of $0.37 to $0.56 3-Month Outlook: Projected fall of -18.07%, reaching $0.58 by October 12, 2026, with a range of $0.50 to $0.67. 1-Year Outlook: Projected gain of 727.8%, with price at $5.86 by July 14, 2027, within a range of $5.79 to $5.92.

Apimeds Pharmaceuticals US, Inc (AMEX:APUS) shares are flat 2.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Apimeds Pharmaceuticals US, Inc trading at a premium to the broader market with a P/E of -0.11. Our AI forecast model points to short-term weakness (-35.02% over two weeks), a medium-term fall (-18.07% over three months), and a longer-term gain (727.8% over one year), with expected trading ranges indicating moderate volatility.